Download PDF
Semin Vasc Med 2002; 02(4): 429-440
DOI: 10.1055/s-2002-36771
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Hemostatic and Rheological Variables and Risk of Cardiovascular Disease

Gordon D.O. Lowe1 , Ann Rumley1 , Peter H. Whincup2 , John Danesh3
  • 1University Department of Medicine, Royal Infirmary, Glasgow, United Kingdom
  • 2Department of Public Health Sciences, St. George's Hospital Medical School, London, United Kingdom
  • 3Department of Public Health and Primary Care, University of Cambridge, United Kingdom
Further Information

Publication History

Publication Date:
22 January 2003 (online)

    Permissions and Reprints

ABSTRACT

Increasing blood levels of hemostatic variables may increase the risk of thrombosis, while increasing levels of rheological variables which reduce blood flow may increase the risk of ischemic events. Systematic reviews of prospective cohort studies of hemostatic and rheological variables suggest that increasing blood levels of fibrinogen, von Willebrand factor, tissue plasminogen activator antigen, fibrin D-dimer, hematocrit, viscosity, and erythrocyte sedimentation rate may be predictors of risk of coronary heart disease (CHD), but their causal relevance is unknown. At present, data for the associations of other hemostatic variables with CHD, and for the associations of hemostatic variables with stroke, venous thromboembolism, and mortality, is relatively sparse and inconclusive. More detailed syntheses of existing prospective data (such as the Fibrinogen Studies Collaboration), observational studies of CHD and the genetic determinants of these plasma components, as well as large-scale randomized trials should help to determine whether or not these associations are (1) useful in prediction of cardiovascular risk and/or (2) of causal significance.

KEYWORD

Coronary heart disease - fibrinogen - coagulation factors - fibrinolysis - fibrin degradation products - blood viscosity

REFERENCES

  • 1 Bloom A L, Forbes C D, Thomas D P, Tuddenham E GD. Haemostasis and Thrombosis, 3rd ed. Edinburgh: Churchill Livingstone 1994
    Google Scholar
  • 2 Emmerich J, Rosendaal F R, Cattaneo M. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism-pooled analysis of 8 case-control studies including 2310 cases and 3204 controls.  Thromb Haemost . 2001;  86 809-816
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Castaman G, Tosetto A, Simioni M. Phenotypic APC resistance in carriers of the A20210 prothrombin mutation is associated with an increased risk of venous thrombosis.  Thromb Haemost . 2001;  86 804-808
    PubMedGoogle Scholar
  • 4 Rosendaal F R. High levels of factor VIII and venous thrombosis.  Thromb Haemost . 2000;  83 1-2
    PubMedGoogle Scholar
  • 5 Lowe G DO, Rumley A, Woodward M. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use.  Br J Haematol . 1997;  97 775-784
    CrossrefPubMedGoogle Scholar
  • 6 Lowe G DO, Rumley A, Woodward M, Reid E, Rumley J. Activated protein C resistance and the FV: R506Q mutation in a random population sample: associations with cardiovascular risk factors and coagulation variables.  Thromb Haemost . 1999;  81 918-924
    PubMedGoogle Scholar
  • 7 Gaffney P J, Brasher M. Subunit structure of the plasmin-induced degradation products of cross-linked fibrin.  Biochem Biophys Acta . 1973;  295 308-313
    PubMedGoogle Scholar
  • 8 Lip G YH, Lowe G DO. Fibrin D-dimer: a useful clinical marker of thrombogenesis?.  Clin Sci . 1995;  89 205-214
    PubMedGoogle Scholar
  • 9 Al-Mohana J MA, Lowe G DO, Murray G D, Burns H G. Association of fibrinolytic tests with outcome of acute upper-gastrointestinal-tract bleeding.  Lancet . 1993;  341 518-521
    CrossrefPubMedGoogle Scholar
  • 10 Lowe G DO. Clinical Blood Rheology Boca Raton, FL: CRC Press 1988: 1-10
  • 11 McCallum P K, Meade T W. Haemostatic function, arterial disease and the prevention of arterial thrombosis.  Bailliere's Clin Haematol . 1999;  12 577-599
    PubMedGoogle Scholar
  • 12 Lowe G DO. Haemostatic risk factors for arterial and venous thrombosis. In: Poller L, Ludlam CA, eds. Recent Advances in Blood Coagulation, 7 Edinburgh: Churchill Livingstone 1997: 69-96
    Google Scholar
  • 13 Reiner A P, Siscovick D S, Rosendaal F R. Hemostatic risk factors and arterial thrombotic disease.  Thromb Haemost . 2001;  85 584-595
    PubMedGoogle Scholar
  • 14 Verstraete M, Fuster V, Topol E J. Cardiovascular Thrombosis 2nd ed. New York: Lippincott-Raven 1998: 23-45
  • 15 Davies M J, Thomas A C. Plaque fissuring-one cause of acute myocardial infarction, sudden ischaemic death and crescendo angina.  Br Heart J . 1985;  53 363-373
    CrossrefPubMedGoogle Scholar
  • 16 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients.  BMJ . 2002;  324 71-86
    CrossrefPubMedGoogle Scholar
  • 17 Meade T W, North W RS, Chakrabarti R. Haemostatic function and cardiovascular death; early results of a prospective study.  Lancet . 1980;  1 1050-1054
    PubMedGoogle Scholar
  • 18 Lowe G DO, Drummond M M, Lorimer A R. Relationship between extent of coronary artery disease and blood viscosity.  Br Med J . 1980;  1 673-674
    PubMedGoogle Scholar
  • 19 Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. Meta-analyses of prospective studies.  JAMA . 1998;  279 1477-1482
    CrossrefPubMedGoogle Scholar
  • 20 Danesh J, Whincup P, Walker M. Low-grade inflammation and coronary heart disease: prospective study and updated meta-analyses.  Br Med J . 2000;  321 199-204
    CrossrefPubMedGoogle Scholar
  • 21 Danesh J, Collins R, Peto R, Lowe G DO. Haematocrit, viscosity, erthryocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease.  Eur Heart J . 2000;  21 515-520
    CrossrefPubMedGoogle Scholar
  • 22 Danesh J, Whincup P, Walker M. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis.  Circulation . 2001;  103 2323-2327
    CrossrefPubMedGoogle Scholar
  • 23 Whincup P, Danesh J, Walker M. Von Willebrand factor and coronary heart disease: new prospective study and meta-analysis.  Eur Heart J . 2002;  23 1766-1770
    PubMedGoogle Scholar
  • 24 Lowe G DO, Danesh J, Rumley A. Tissue plasminogen activator antigen and coronary heart disease: new prospective study and meta-analysis.  Blood Coagul Fibrinolysis. 12 A1-A2
    PubMedGoogle Scholar
  • 25 Lewis M R, Callas P W, Jenny N S, Tracy R P. Longitudinal stability of coagulation, fibrinolysis, and inflammation factors in stored plasma samples.  Thromb Haemost . 2001;  86 1495-1500
    PubMedGoogle Scholar
  • 26 Lowe G DO, Smith W CS, Tunstall-Pedoe H D. Cardiovascular risk and haemorheology-results from the Scottish Heart Health Study and the MONICA Project, Glasgow.  Clin Hemorheol . 1988;  8 518-524
    PubMedGoogle Scholar
  • 27 Rumley A. Fibrinolytic and endothelial markers in cardiovascular disease and diabetes mellitus [Ph.D  thesis]. Glasgow: University of Glasgow 1996
    Google Scholar
  • 28 Bashir S A, Duffy S W, Qizilbash N. Repeat measurement of case-control data: corrections for measurement error in a study of ischaemic stroke and haemostatic factors.  Int J Epidemiol . 1997;  26 64-70
    CrossrefPubMedGoogle Scholar
  • 29 Sakkinen P A, Macy E M, Callas P W. Analytic and biologic variability in measures of hemostasis, fibrinolysis and inflammation: assessment and implications for epidemiology.  Am J Epidemiol . 1999;  149 261-267
    PubMedGoogle Scholar
  • 30 Emberson J R, Whincup P H, Morris R W. Regression dilution of established and novel coronary risk factors: results from the British Regional Heart Study. Submitted for publication. 
    PubMedGoogle Scholar
  • 31 Lowe G DO. Fibrinogen-A Cardiovascular Risk Factor.  Mannheim, Germany: Boehringer Mannheim 1997: 1-63
    Google Scholar
  • 32 Lowe G DO. Fibrinogen: an independent coronary heart disease risk factor. In: Betteridge DJ, ed. Lipids and Vascular Disease London: Dunitz 2000: 77-84
    Google Scholar
  • 33 Maresca G, Di Blasio A, Marchioli R, Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update.  Arterioscler Thromb Vasc Biol . 1999;  19 1368-1377
    CrossrefPubMedGoogle Scholar
  • 34 Lowe G DO, Fowkes F GR, Dawes J. Blood viscosity, fibrinogen and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study.  Circulation . 1993;  87 1915-1920
    CrossrefPubMedGoogle Scholar
  • 35 Lee A J, Mowbray P I, Lowe G DO. Blood viscosity and elevated carotid intima-media thickness in men and women: the Edinburgh Artery Study.  Circulation . 1998;  97 1467-1473
    PubMedGoogle Scholar
  • 36 Wilhelmsen L, Svardsudd K, Korsan-Bengsten K. Fibrinogen as a risk factor for stroke and myocardial infarction.  N Engl J Med . 1984;  311 501-505
    CrossrefPubMedGoogle Scholar
  • 37 Lowe G DO, Lee A J, Rumley A. Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study.  Br J Haematol . 1997;  96 168-173
    CrossrefPubMedGoogle Scholar
  • 38 Bainton D, Sweetnam P, Baker I. Peripheral vascular disease. Consequence for survival and association with risk factors in the Speedwell Prospective Heart Disease Study.  Br Heart J . 1994;  72 128-132
    CrossrefPubMedGoogle Scholar
  • 39 Smith F B, Lee A J, Hau C. Plasma fibrinogen, haemostatic factors and prediction of peripheral arterial disease in the Edinburgh Artery Study.  Blood Coagul Fibrinol . 2000;  11 43-50
    PubMedGoogle Scholar
  • 40 Koster T, Rosendaal F R, Reitsma P H. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms. Leiden Thrombophilia Study (LETS).  Thromb Haemost . 1994;  71 719-722
    PubMedGoogle Scholar
  • 41 Kannel W B. Influence of fibrinogen on cardiovascular disease.  Drugs . 1997;  54 S32-S40
    PubMedGoogle Scholar
  • 42 Woodward M, Lowe G DO, Rumley A, Tunstall-Pedoe H. Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women-the Scottish Heart Health Study.  Eur Heart J . 1998;  19 55-62
    CrossrefPubMedGoogle Scholar
  • 43 Sweetnam P M, Yarnell J WG, Lowe G DO. The relative power of heat-precipitation nephelometric and clottable (Clauss) fibrinogen in the prediction of ischaemic heart disease: the Caerphilly and Speedwell studies.  Br J Haematol . 1998;  100 582-588
    CrossrefPubMedGoogle Scholar
  • 44 Lowe G DO, Rumley A, Mackie I J. Analytical review: plasma fibrinogen (in press).  Ann Biochem.
    PubMedGoogle Scholar
  • 45 Lee A J, Smith W CS, Lowe G DO, Tunstall-Pedoe H. Plasma fibrinogen and coronary risk factors: the Scottish Heart Health Study.  J Clin Epidemiol . 1990;  43 913-919
    CrossrefPubMedGoogle Scholar
  • 46 Simmonds R E, Hermida J, Rezende S M, Lane D A. Haemostatic genetic risk factors in arterial thrombosis.  Thromb Haemost . 2001;  86 374-385
    PubMedGoogle Scholar
  • 47 Lane D A, Grant P J. Role of hemostatic gene polymorphisms in venous and arterial thrombosis.  Blood . 2000;  95 1517-1532
    PubMedGoogle Scholar
  • 48 Lowe G DO. Ancrod in treatment of acute ischaemic stroke.  Proc R Coll Phys Edin . 2001;  31(Suppl 8) 20-24
    PubMedGoogle Scholar
  • 49 Lowe G DO. Rheological influences on thrombosis.  Bailliere's Clin Haematol . 1994;  7 573-589
    PubMedGoogle Scholar
  • 50 Sweetnam P M, Thomas H F, Yarnell J WG. Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease. The Caerphilly and Speedwell studies.  Eur Heart J . 1996;  17 1814-1820
    PubMedGoogle Scholar
  • 51 Lowe G DO, Rumley A, Norrie J, on behalf of the West of Scotland Coronary Prevention Group. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study.  Thromb Haemost . 2000;  84 553-558
    PubMedGoogle Scholar
  • 52 Rumley A, Lowe G DO, Sweetnam P M, Yarnell J WG, Ford R P. Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Study.  Br J Haematol . 1999;  105 110-116
    CrossrefPubMedGoogle Scholar
  • 53 Brinkhous K M, Reddick R L, Read M S. Von Willebrand's factor and animal models: contributions to gene therapy, thrombotic thrombocytopenic purpura, and coronary artery thrombosis.  Mayo Clin Proc . 1991;  66 733-742
    PubMedGoogle Scholar
  • 54 Meade T W, Cooper J C, Stirling Y. Factor VIII, ABO blood group and the incidence of ischaemic heart disease.  Br J Haematol . 1994;  88 601-607
    CrossrefPubMedGoogle Scholar
  • 55 Smith F B, Lee A J, Fowkes F GR. Hemostatic factors as predictors of ischaemic heart disease and stroke in the Edinburgh Artery Study.  Arterioscler Thromb Vasc Biol . 1997;  17 3321-3325
    PubMedGoogle Scholar
  • 56 Folsom A R, Wu K K, Rosamond W D, Sharrett A R, Chabless L E. Prospective study of hemostatic factors and incidence of coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) study.  Circulation . 1997;  96 1102-1108
    CrossrefPubMedGoogle Scholar
  • 57 Stephoe A, Kunz-Ebrecht S, Rumley A, Lowe G DO. Prolonged elevations in haemostatic and rheological responses following psychological forces in low socioeconomic status men and women (in press).  Thromb Haemost.
    PubMedGoogle Scholar
  • 58 Wannamethee S G, Lowe G DO, Whincup P H. Physical activity and hemostatic and inflammatory variables in elderly men.  Circulation . 2002;  105 1785-1790
    CrossrefPubMedGoogle Scholar
  • 59 Rosendaal F R, Briet E, Stibbe J. Haemophilia protects against ischaemic heart disease: a study of risk factors.  Br J Haematol . 1990;  75 525-530
    PubMedGoogle Scholar
  • 60 Lowe G DO. Factor IX and thrombosis.  Br J Haematol . 2001;  115 507-513
    CrossrefPubMedGoogle Scholar
  • 61 Meade T W, Ruddock V, Stirling Y, Chakrabati R, Miller G J. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study.  Lancet . 1993;  342 1076-1079
    CrossrefPubMedGoogle Scholar
  • 62 Junker R, Heinrich J, Schulte H, van de Loo J, Assmann G. Coagulation factor VII and the risk of coronary heart disease in healthy men.  Arterioscler Thromb Vasc Biol . 1997;  17 1539-1544
    CrossrefPubMedGoogle Scholar
  • 63 Lowe G DO, Rumley A, Sweetnam P, Yarnell J WG, RumleyJ. Fibrin D-dimer, markers of coagulation activation, and the risk of major ischaemic heart disease in the Caerphilly Study.  Thromb Haemost . 2001;  86 822-827
    PubMedGoogle Scholar
  • 64 Cooper J A, Miller G J, Bauer K A. Comparison of novel haemostatic factors and conventional risk factors for prediction of coronary heart disease.  Circulation . 2000;  102 2816-2822
    PubMedGoogle Scholar
  • 65 The Medical Research Council's General Practice Research Framework. Thrombosis Prevention Trial.  Lancet . 1998;  351 233-241
    CrossrefPubMedGoogle Scholar
  • 66 Meade T W, Cooper J A, Miller G J. Platelet counts and aggregation measures in the incidence of ischaemic heart disease (IHD).  Thromb Haemost . 1997;  78 926-929
    PubMedGoogle Scholar
  • 67 Elwood P C, Beswick A, Pickering J. Platelet tests in the prediction of myocardial infarction and ischaemic stroke: evidence from the Caerphilly Prospective Study.  Br J Haematol . 2001;  113 514-520
    CrossrefPubMedGoogle Scholar
  • 68 Martin J F, Bath P MW, Burr M L. Influence of platelet size on outcome after myocardial infarction.  Lancet . 1991;  338 1409-1411
    CrossrefPubMedGoogle Scholar
  • 69 Trip M D, Cats V M, van Capelle J L F, Breeken J. Platelet hyper-reactivity and prognosis in survivors of myocardial infarction.  N Engl J Med . 1990;  322 1549-1554
    CrossrefPubMedGoogle Scholar
  • 70 Booth N A. Fibrinolysis and thrombosis.  Bailliere's Clin Haematol . 1999;  12 423-433
    PubMedGoogle Scholar
  • 71 De Bono D. Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease.  Br Heart J . 1994;  71 504-507
    PubMedGoogle Scholar
  • 72 Smith F B, Fowkes F GR, Hau C M. Tissue plasminogen activator and leucocyte elastase as predictors of cardiovascular events in subjects with angina pectoris: Edinburgh artery study.  Eur Heart J . 2000;  21 1607-1613
    CrossrefPubMedGoogle Scholar
  • 73 Lowe G DO, Woodward M, Vessey M P. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years: relationships to hormone replacement therapy.  Thromb Haemost . 2000;  83 530-535
    PubMedGoogle Scholar
  • 74 Lowe G DO, Haverkate F, Thompson S G, on behalf of the ECAT DVT Study Group. Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: the ECAT DVT Study.  Thromb Haemost . 1999;  81 879-886
    PubMedGoogle Scholar
  • 75 McMahon A J, O'Dwyer P J, Cruickshank A M. Comparison of metabolic responses to laparoscopic and minilaparotomy cholecystectomy.  Br J Surg . 1993;  80 1255-1258
    PubMedGoogle Scholar
  • 76 Lowe G DO, Yarnell J WG, Rumley A, Bainton D, Sweetnam P M. C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell Study. Are inflammation and fibrin turnover linked in pathogenesis?.  Arterioscler Thromb Vasc Biol . 2001;  21 603-610
    PubMedGoogle Scholar
  • 77 Lip G YH, Lowe G DO, Rumley A, Dunn F G. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment.  Br Heart J . 1995;  73 527-533
    PubMedGoogle Scholar
  • 78 Lip G YH, Zafiris J, Watson R DS. Fibrin D-dimer and β-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin.  Circulation . 1996;  94 425-431
    PubMedGoogle Scholar
      >